The effectiveness of Tricine as an adyuvante of cisplatin in the treatment of cutaneous squamous carcinoma is demonstrated using Synchrotron technology

Dr. Silvia Gil, active member of the cancer research group of I3PT Parc Tauli, has Performed in collaboration with researchers at the ALBA Synchrotron Facility a study Titled "multiparamétrico analysis of the cisplatin effectiveness donde cutaneous squamous carcinoma cells by using two different types of adyuvantes".

The objective of the study was to Regulate the level of cytotoxicity of cisplatin (cisPt) in order to minimize its Adverse effects. To this purpose, the lowest cisPt concentration necessary [3.5 micras] to obtain a significante positive response in cutaneous squamous cell carcinoma (CSCC) was explored. Two adyuvante agentes namely gold nanoparticles (AuNP) [2.5 mM] and chelating tricine [50 mM] were tested as enhancers in cisPt treatments. In fact, tricine is widely used as a biological buffer in nuclear medicine.

Results were obtained through the combination of conventional biological based techniques and cryo soft X-ray tomography (cryo-SXT) in Mistral beamline at ALBA, which suggested that there is not covalente bonding between AuNP and the commercial version of cisPt. However, some moléculas of cisPt might be electrostatically linked to AuNP, which facilidades cell penetration and might cause a damage thereof and a Slight increase of necrótica cell death.

On the other side, treatment based on the combination of cisPt with tricine Enhancer drug effectiveness, with a noticeable increase in cell death, specially vía apoptosis, thus Becoming a better adyuvante in cisPt treatments.

Notwithstanding the positive results of the study, further research is needed to determina el mechanismus making the combination of cisPt and tricine more effective.

Documentos of interest:

• Gy S, Yébenes M, Luelmo J, Alsina M, Sabés M. A comparartive study of the effectiveness of cisplatin and 5-fluorouracilo donde cutaneous squamous human carcinoma cell line: Potential chemotherapy alternative to surgery. Dermatol Ther. 2016; 29: 341-344. https://www.ncbi.nlm.nih.gov/pubmed/27292650
• Sorrentino A, Nicolás J, Valcárcel R, Chichón FJ, Rosanes M, Avila J, Tkachuk A, Irwin J, Ferrer S, Pereiro E. MISTRAL: a transmisión soft X-ray microscopy beamline for cryo nano-tomography of biological samples and magnetic domains imaging. J Synchrotron Rad. 2015; 22: 1112/1117.  https://www.ncbi.nlm.nih.gov/pubmed/26134819
• Zheng DL, Long Y, Tsai WB, Fu S, Kurzrock R, Gagea-Iurascu M, Zhang F, Chen H, Hennessy B, Mills G, Savaraj N, Kuo MT. Mechanistic Basis for Overcoming Platinum Resistance Using Copper Chelating Agentes. Mol Cancer Ther. 2012; 11 (11): 2483-2494. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3496003/